New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCartalax vs Teduglutide

Cartalax vs Teduglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cartalax
Recovery & Repair
Teduglutide
Summary
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
Half-Life
Short (minutes); gene-regulatory effects are sustained
~2 hours; once-daily dosing due to gut-specific residence
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.05 mg/kg/day
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
  • Increases intestinal villus height and absorption surface area
  • Reduces intestinal permeability (leaky gut)
  • FDA-approved for short bowel syndrome
  • Reduces parenteral nutrition dependence in SBS patients
  • Promotes intestinal mucosal healing in IBD
  • Increases tight junction proteins ZO-1 and occludin
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
  • Injection site reactions
  • Abdominal pain and bloating
  • Nausea
  • Risk of intestinal polyp growth (requires colonoscopy surveillance)
  • +1 more
Stacks With